A new study in the New England Journal of Medicine reports promising results from a CRISPR gene-editing therapy in children aged 5 to 11. The children had severe sickle cell disease or transfusion-dependent beta thalassaemia, both inherited blood disorders. HCA Healthcare announced the research, which was led by Dr Haydar Frangoul and sponsored by Vertex Pharmaceuticals.

The therapy is exagamglogene autotemcel, known as exa-cel. This is the first published data evaluating it in this younger age group. Earlier trials supported approvals for patients aged 12 and older in the United States, the United Kingdom and the European Union.

​

Treating younger children matters because both conditions cause cumulative damage from early in life. A therapy that works at ages 5 to 11 makes earlier intervention possible.

It also marks a shift for the technology. CRISPR gene editing has moved from first approvals to expanding eligibility in only a few years. The science is maturing, and the commercial pipeline behind it is scaling.

Regulatory approval in one country does not mean access in another. Each therapy must clear its own national pathways for registration and reimbursement before patients can reach it.

For Australia, that is the harder problem. One-time gene therapies carry high upfront prices. This therapy has a United States list price of about US$2.2 million. Funding models built for conventional medicines do not map neatly onto a single, one-time treatment.

This is where a coordinated industry voice matters. Getting proven genomic therapies to Australian patients depends on regulatory pathways, reimbursement decisions and the systems that assess value. InGeNA works on those pathways with government.

News like this shows what the genomics industry can now deliver. Closing the gap between what is scientifically possible and what Australians can access is the reason InGeNA exists.

Read the original announcement from HCA Healthcare.

Advances like this reach Australian patients only when the pathways behind them work. The InGeNA newsletter tracks the policy, reimbursement and market access decisions that decide whether they do.
Subscribe to the InGeNA newsletter today to keep up with our rapidly-growing sector.